Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer

H. O. Smith; G. L. Goldberg; L. Carol; S. A. Davidson; C. Tomaino; L. Centrilla; C. D. Runowicz

Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer

H. O. Smith, G. L. Goldberg, L. Carol, S. A. Davidson, C. Tomaino, L. Centrilla, C. D. Runowicz

Obstetrics & Gynecology and Women's Health

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Dose intensification chemotherapy is currently under investigation in ovarian cancer. In order to establish an optimum dose for future colony stimulating factor trials, 16 patients with ovarian cancer were treated with dose-escalation combination carboplatin plus cyclophosphamide chemotherapy without growth factors. The initial carboplatin dose, 300 mg/m², was increased to a maximum dose of 400 mg/m². The initial cyclophosphamide dose, 600 mg/m², was increased to a maximum dose of 1200 mg/m². Of 10 patients completing 6 cycles, six patients (60%) were escalated to carboplatin 400 mg/m² and cyclophosphamide 600-1200 mg/m². Myelosuppression was severe, with all 6 patients requiring platelet and/or packed red blood cell transfusions. Based on these results, carboplatin 400 mg/m² with cyclophosphamide 600 mg/m² was selected as the starting dose with hematopoietic growth factors,

Original language	English (US)
Pages (from-to)	411-417
Number of pages	7
Journal	European Journal of Gynaecological Oncology
Volume	15
Issue number	6
State	Published - 1994

Keywords

Carboplatin
Chemotherapy
Ovarian cancer

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{4d00ef5fb3324de0b83a97110e4d9d81,

title = "Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer",

abstract = "Dose intensification chemotherapy is currently under investigation in ovarian cancer. In order to establish an optimum dose for future colony stimulating factor trials, 16 patients with ovarian cancer were treated with dose-escalation combination carboplatin plus cyclophosphamide chemotherapy without growth factors. The initial carboplatin dose, 300 mg/m2, was increased to a maximum dose of 400 mg/m2. The initial cyclophosphamide dose, 600 mg/m2, was increased to a maximum dose of 1200 mg/m2. Of 10 patients completing 6 cycles, six patients (60%) were escalated to carboplatin 400 mg/m2 and cyclophosphamide 600-1200 mg/m2. Myelosuppression was severe, with all 6 patients requiring platelet and/or packed red blood cell transfusions. Based on these results, carboplatin 400 mg/m2 with cyclophosphamide 600 mg/m2 was selected as the starting dose with hematopoietic growth factors,",

keywords = "Carboplatin, Chemotherapy, Ovarian cancer",

author = "Smith, {H. O.} and Goldberg, {G. L.} and L. Carol and Davidson, {S. A.} and C. Tomaino and L. Centrilla and Runowicz, {C. D.}",

year = "1994",

language = "English (US)",

volume = "15",

pages = "411--417",

journal = "European Journal of Gynaecological Oncology",

issn = "0392-2936",

publisher = "S.O.G. CANADA Inc.",

number = "6",

}

TY - JOUR

T1 - Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer

AU - Smith, H. O.

AU - Goldberg, G. L.

AU - Carol, L.

AU - Davidson, S. A.

AU - Tomaino, C.

AU - Centrilla, L.

AU - Runowicz, C. D.

PY - 1994

Y1 - 1994

N2 - Dose intensification chemotherapy is currently under investigation in ovarian cancer. In order to establish an optimum dose for future colony stimulating factor trials, 16 patients with ovarian cancer were treated with dose-escalation combination carboplatin plus cyclophosphamide chemotherapy without growth factors. The initial carboplatin dose, 300 mg/m2, was increased to a maximum dose of 400 mg/m2. The initial cyclophosphamide dose, 600 mg/m2, was increased to a maximum dose of 1200 mg/m2. Of 10 patients completing 6 cycles, six patients (60%) were escalated to carboplatin 400 mg/m2 and cyclophosphamide 600-1200 mg/m2. Myelosuppression was severe, with all 6 patients requiring platelet and/or packed red blood cell transfusions. Based on these results, carboplatin 400 mg/m2 with cyclophosphamide 600 mg/m2 was selected as the starting dose with hematopoietic growth factors,

AB - Dose intensification chemotherapy is currently under investigation in ovarian cancer. In order to establish an optimum dose for future colony stimulating factor trials, 16 patients with ovarian cancer were treated with dose-escalation combination carboplatin plus cyclophosphamide chemotherapy without growth factors. The initial carboplatin dose, 300 mg/m2, was increased to a maximum dose of 400 mg/m2. The initial cyclophosphamide dose, 600 mg/m2, was increased to a maximum dose of 1200 mg/m2. Of 10 patients completing 6 cycles, six patients (60%) were escalated to carboplatin 400 mg/m2 and cyclophosphamide 600-1200 mg/m2. Myelosuppression was severe, with all 6 patients requiring platelet and/or packed red blood cell transfusions. Based on these results, carboplatin 400 mg/m2 with cyclophosphamide 600 mg/m2 was selected as the starting dose with hematopoietic growth factors,

KW - Carboplatin

KW - Chemotherapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0028143976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028143976&partnerID=8YFLogxK

M3 - Article

C2 - 7875155

AN - SCOPUS:0028143976

SN - 0392-2936

VL - 15

SP - 411

EP - 417

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

IS - 6

ER -

Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this